Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trialXiaotian Zhang, Jiafu Ji, Yanong Wang et al.|The Lancet Oncology|2021Cited by 436
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Xiaofeng Zeng, Ying Jiang et al.|Annals of the Rheumatic Diseases|2025Cited by 17